Clinical Trials Logo

Diabetic Cardiomyopathies clinical trials

View clinical trials related to Diabetic Cardiomyopathies.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04141475 Terminated - Clinical trials for Diabetic Cardiomyopathies

Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy

CARDIALA
Start date: November 24, 2020
Phase: N/A
Study type: Interventional

The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.